PCOS: The 2018 Guidelines for the Diagnosis and Treatment of Polycystic Ovary Syndrome in China define the diagnostic criteria for adolescent PCOS, which include the following four conditions: 1) oligomenorrhea after menarche lasting at least 2 years or amenorrhea
Conditions
Interventions
Group treated with GnRHa:None
Observation group:None
Group treated with GnRHa and rhGH:None
Sponsors
Suzhou Science & Technology Town Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.Consistent with the diagnosis of CPP or EFP. (1) CPP: 1) Girls with breast development before 7.5 years old or menarche before 10 years old; 2) Linear growth or sexual development in Tanner stage were accelerated , and the advancement of bone age exceeds >= 1 year the chronological age; 3) Pelvic B-ultrasound revealed the enlargement of ovarian with volume > 1 ml (ovarian volume = length × width × thickness × 0.5233) or multiple follicle? with diameter >= 4 mm; 4) LH peak value from GnRH stimulation >= 5.0 U/L and the LH to FSH peak value ratio >= 0.6; (2) EFP: 1) Girls with breast development between 8 to 10 years old; 2) Type with rapid progresion (characterized by rapid sexual development, less than 6 months to advance to the next stage; Within a brief period Swift advancement of skeletal maturation, with a significant discrepancy over chronological age); 3) Linear growth or sexual development in Tanner stage were accelerated , and the advancement of bone age exceeds >= 1 year the chronological age; 4) Pelvic B-ultrasound revealed the enlargement of ovarian with volume > 1 ml (ovarian volume = length × width × thickness × 0.5233) or multiple follicle? with diameter >= 4 mm; 5) LH peak value from GnRH stimulation >= 5.0 U/L and the LH to FSH peak value ratio >= 0.6; 2.Adrenocortical hyperplasia, hypothyroidism, Cushing's syndrome, androgen-secreting tumors, and other related endocrine diseases were excluded; 3.The medication group's treatment course should be at least one year; 4.Parents were informed and gave their consent to participate in the study;
Exclusion criteria
Exclusion criteria: 1.Serious systemic diseases and long-term chronic drug treatment; 2.Use of other hormone drugs within the past six months; 3.Any other condition deemed inappropriate for inclusion in the study by the investigator;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of PCOS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual development indicators, growth-related indicators, metabolic indicators.;Liver and kidney function, thyroid function, insulin-like growth factor-1 (IGF-1), incidence of adverse events (AEs) and serious adverse events (SAEs).; | — |
Countries
China
Contacts
Public Contactzhimin ma
Suzhou Science & Technology Town Hospital
Outcome results
None listed